{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:54:02Z","timestamp":1787032442867,"version":"build-2736575974"},"reference-count":30,"publisher":"e-Century Publishing Corporation","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nucl Med Mol Imaging"],"DOI":"10.62347\/incg3525","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T05:34:36Z","timestamp":1730352876000},"page":"337-344","source":"Crossref","is-referenced-by-count":6,"title":["Normal-organ distribution of PSMA-targeting PET radiopharmaceutical 18F-flotufolastat: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies"],"prefix":"10.62347","volume":"14","author":[{"given":"Ross","family":"Penny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","unstructured":"FDA. FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer. 2020."},{"key":"ref1","unstructured":"NCCN. NCCN clinical practice guidelines in oncology: prostate cancer. Version 3.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. 2024."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM and Tilki D. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 2024; 86: 148-163.","journal-title":"Eur Urol"},{"key":"ref3","unstructured":"FDA. Highlights of prescribing information: PYLARIFY® (piflufolastat F 18) injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214793s000lbl.pdf, 2021."},{"key":"ref4","unstructured":"FDA. Highlights of prescribing information: Gallium Ga 68 PSMA-11 Injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212642s000lbl.pdf, 2020."},{"key":"ref5","unstructured":"FDA. Highlights of prescribing information: POSLUMA (flotufolastat F 18) injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216023s000lbl.pdf, 2023."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.119.234922","article-title":"Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors","volume":"61","author":"Wurzer","year":"2020","unstructured":"Wurzer A, Di Carlo D, Schmidt A, Beck R, Eiber M, Schwaiger M and Wester HJ. Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors. J Nucl Med 2020; 61: 735-742.","journal-title":"J Nucl Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE)","volume":"84","author":"DS","year":"2023","unstructured":"Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM and Chapin BF; LIGHTHOUSE Study Group. Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur Urol 2023; 84: 361-370.","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/JU.0000000000003493","article-title":"3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)","volume":"210","author":"AB","year":"2023","unstructured":"Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF and Schuster DM; SPOTLIGHT Study Group. Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol 2023; 210: 299-311.","journal-title":"J Urol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101532","DOI":"10.1016\/j.adro.2024.101532","article-title":"Impact of clinical factors on 18F-flotufolastat detection rates in men with recurrent prostate cancer: exploratory analysis of the phase 3 SPOTLIGHT Study","volume":"9","author":"Lowentritt","year":"2024","unstructured":"Lowentritt BH, Jani AB, Helfand BT, Uchio EM, Morris MA, Michalski JM, Chau A, Davis P, Chapin BF and Schuster DM. Impact of clinical factors on 18F-flotufolastat detection rates in men with recurrent prostate cancer: exploratory analysis of the phase 3 SPOTLIGHT Study. Advances in Radiation Oncology 2024; 9: 101532.","journal-title":"Advances in Radiation Oncology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11307-023-01867-w","article-title":"Quantitative and qualitative assessment of urinary activity of 18F-flotufolastat-PET\/CT in patients with prostate cancer: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies","volume":"26","author":"Kuo","year":"2024","unstructured":"Kuo PH, Hermsen R, Penny R and Postema EJ. Quantitative and qualitative assessment of urinary activity of 18F-flotufolastat-PET\/CT in patients with prostate cancer: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies. Mol Imaging Biol 2024; 26: 53-60.","journal-title":"Mol Imaging Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2967\/jnumed.120.252114","article-title":"3 in healthy adult volunteers","volume":"62","author":"Tolvanen","year":"2021","unstructured":"Tolvanen T, Kalliokoski K, Malaspina S, Kuisma A, Lahdenpohja S, Postema EJ, Miller MP and Scheinin M. Safety, biodistribution, and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers. J Nucl Med 2021; 62: 679-684.","journal-title":"J Nucl Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"0","volume":"50","author":"Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schoder H, Wan S, Wester HJ, Hope TA and Herrmann K. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 2023; 50: 1466-1486.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Hope TA and Jadvar H. Updates to appropriate use criteria for PSMA PET. J Nucl Med 2022; 63: 14N.","DOI":"10.2967\/jnumed.121.263262"},{"key":"ref14","unstructured":"FDA. FDA approves Pluvicto for metastatic castration-resistant prostate cancer: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. 2022."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ and Krause BJ; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385: 1091-1103.","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","author":"Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY and Pomper MG. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 2015; 17: 565-574.","journal-title":"Mol Imaging Biol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","unstructured":"Ferreira G, Iravani A, Hofman MS and Hicks RJ. Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution. Cancer Imaging 2019; 19: 23.","journal-title":"Cancer Imaging"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13550-023-01033-x","article-title":"Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer","volume":"13","author":"Heilinger","year":"2023","unstructured":"Heilinger J, Weindler J, Roth KS, Krapf P, Schomacker K, Dietlein M, Drzezga A and Kobe C. Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer. EJNMMI Res 2023; 13: 83.","journal-title":"EJNMMI Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2967\/jnumed.123.267042","article-title":"3","volume":"65","author":"Hope","year":"2024","unstructured":"Hope TA and Jadvar H. PSMA PET AUC updates: inclusion of rh-PSMA-7.3. J Nucl Med 2024; 65: 540.","journal-title":"J Nucl Med"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Wahl RL, Jacene H, Kasamon Y and Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 Suppl 1: 122S-150S.","DOI":"10.2967\/jnumed.108.057307"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U and Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486-495.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s11307-016-0945-x","article-title":"Biodistribution of [68Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions","volume":"18","author":"Prasad","year":"2016","unstructured":"Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P and Brenner W. Biodistribution of [68Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol 2016; 18: 428-436.","journal-title":"Mol Imaging Biol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2967\/jnumed.121.263371","article-title":"Synthesis and preclinical evaluation of 177Lu-labeled radiohybrid PSMA ligands for endoradiotherapy of prostate cancer","volume":"63","author":"Wurzer","year":"2022","unstructured":"Wurzer A, Kunert JP, Fischer S, Felber V, Beck R, Rose F, D’Alessandria C, Weber W and Wester HJ. Synthesis and preclinical evaluation of 177Lu-labeled radiohybrid PSMA ligands for endoradiotherapy of prostate cancer. J Nucl Med 2022; 63: 1489-1495.","journal-title":"J Nucl Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13550-020-00740-z","article-title":"Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics","volume":"10","author":"Wurzer","year":"2020","unstructured":"Wurzer A, Parzinger M, Konrad M, Beck R, Günther T, Felber V, Färber S, Di Carlo D and Wester HJ. Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics. EJNMMI Res 2020; 10: 149.","journal-title":"EJNMMI Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2967\/jnumed.120.260091","article-title":"3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment","volume":"62","author":"Rauscher","year":"2021","unstructured":"Rauscher I, Karimzadeh A, Schiller K, Horn T, D’Alessandria C, Franz C, Worther H, Nguyen N, Combs SE, Weber WA and Eiber M. Detection efficacy of 18F-rhPSMA-7.3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment. J Nucl Med 2021; 62: 1719-1726.","journal-title":"J Nucl Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III, multicenter study","volume":"27","author":"MJ","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, Lin T, Stambler N, Carroll PR and Siegel BA; CONDOR Study Group. Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III, multicenter study. Clin Cancer Res 2021; 27: 3674-3682.","journal-title":"Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J and Hope TA. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 2019; 5: 856-863.","journal-title":"JAMA Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"SF","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A and Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32: 3048-3058.","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG and Sandhu S. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19: 825-833.","journal-title":"Lancet Oncol"}],"container-title":["American Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajnmmi\/14\/5\/ajnmmi0157544.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:58:02Z","timestamp":1766023082000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajnmmi\/14\/5\/ajnmmi0157544.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/incg3525","relation":{},"ISSN":["2160-8407"],"issn-type":[{"value":"2160-8407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}